Assistant Professor, Medicine, Case Western Reserve University School of Medicine
Oncology
Dr. Frederic J. Reu, MD
|
|
Give Review
Frederic is an expert in the field of Oncology. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Frederic is also a published doctor. He has 15 paper published. The most recent paper is: Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-cancer agent. Dr. Frederic J. Reu accepts Medicare.
Publications
- Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-Cancer agent.
- Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, Vincristine, Dexamethasone, and Lenalidomide combination therapy followed by lenalidomide mainte...
- Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in Myeloid malignancies.
- Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis.
- Direct Chromatin PCR (DC-PCR): Hypotonic Conditions Allow Differentiation of Chromatin States during Thermal Cycling.
- Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma Cells by DNA demethylation.
- Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
- Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma Cells to interferons (IFNs) or Apo...
- Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma Cells to Apo2L/TRAIL-induced apoptosis.
- p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies.
- Type 1 cryoglobulinemia: response to thalidomide and lenalidomide.
- Idiopathic systemic capillary leak syndrome preceding diagnosis of infiltrating lobular Carcinoma of the breast with quiescence during neoadjuvant chemotherapy.
- Undifferentiated thyroglobulin-positive thyroid Cancer 45 years after treatment for papillary primary.
- Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Cleveland Clinic Foundation -
Eberhard Karls University Faculty of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1750543963 | |
| NPPES Provider LastName | REU | |
| NPPES Provider FirstName | FREDERIC | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1290.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 134.0 | |
| Percent Opioid Claims | 10.39 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1750543963 |
| Last Name Of The Provider | REU |
| First Name Of The Provider | FREDERIC |
| View All |
Similar Doctors
|
|
Dr. Nathan E. Langer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles J. Nock, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aric W. Greenfield, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Henry B. Koon Jr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Dale H. Cowan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Cooper, MD |
|
|
Dr. Daniel Y. Heng, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nathan A. Pennell, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ashley E. Rosko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vamsidhar Velcheti, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Betty K. Hamilton, MD
This Doctor is OpenDoctor Recommended.
|